- Home
- ARMP vs TGHL Comparison
ARMP vs TGHL Comparison
Compare ARMP & TGHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- TGHL
- Stock Information
- Founded
- ARMP N/A
- TGHL 2020
- Country
- ARMP United States
- TGHL Singapore
- Employees
- ARMP N/A
- TGHL N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- TGHL EDP Services
- Sector
- ARMP Health Care
- TGHL Technology
- Exchange
- ARMP Nasdaq
- TGHL Nasdaq
- Market Cap
- ARMP 92.4M
- TGHL 86.8M
- IPO Year
- ARMP N/A
- TGHL 2025
- Fundamental
- Price
- ARMP $2.94
- TGHL $1.94
- Analyst Decision
- ARMP Strong Buy
- TGHL
- Analyst Count
- ARMP 1
- TGHL 0
- Target Price
- ARMP $9.00
- TGHL N/A
- AVG Volume (30 Days)
- ARMP 12.5K
- TGHL 808.5K
- Earning Date
- ARMP 11-12-2025
- TGHL 01-01-0001
- Dividend Yield
- ARMP N/A
- TGHL N/A
- EPS Growth
- ARMP N/A
- TGHL N/A
- EPS
- ARMP N/A
- TGHL N/A
- Revenue
- ARMP $6,868,000.00
- TGHL $173,668.00
- Revenue This Year
- ARMP $8.43
- TGHL N/A
- Revenue Next Year
- ARMP N/A
- TGHL N/A
- P/E Ratio
- ARMP N/A
- TGHL N/A
- Revenue Growth
- ARMP 84.67
- TGHL 84.40
- 52 Week Low
- ARMP $0.90
- TGHL $1.80
- 52 Week High
- ARMP $3.14
- TGHL $4.25
- Technical
- Relative Strength Index (RSI)
- ARMP 61.74
- TGHL N/A
- Support Level
- ARMP $2.79
- TGHL N/A
- Resistance Level
- ARMP $3.03
- TGHL N/A
- Average True Range (ATR)
- ARMP 0.15
- TGHL 0.00
- MACD
- ARMP 0.02
- TGHL 0.00
- Stochastic Oscillator
- ARMP 72.97
- TGHL 0.00
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.